Анти-IgЕ терапия при деца.

Immunoglobulin E (IgE) and mast cells play a key role in various allergic diseases. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved the control of these diseases and ushered in a new era in the treatment of severe allergic conditions. Long-term experience with omalizumab in severe allergic asthma has confirmed its effectiveness and safety, reducing the symptoms and incidence of severe exacerbations in patients. In addition to treating severe asthma, Omalizumab has been approved for the treatment of chronic spontaneous urticaria (CSU), and although the mechanisms underlying the action of omalizumab in CSU are not fully understood, almost 90% of CSU patients show complete or partial response to omalizumab treatment. Omalizumab has also recently been approved for the treatment of severe Japanese cedar pollinosis (JC) based on the successful results of a study of omalizumab in inadequately controlled severe hay fever treated with antihistamines and nasal corticosteroids. In recent years, there have been a number of scientific publications showing the successful off-label use of omalizumab in diseases in which IgE plays a key role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, non-atopic asthma, mastocytosis, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, systemic lupus and contact dermatitis. Its safe use in pregnant women with asthma, as well as the concomitant use of omalizumab and allergen-specific immunotherapy, has already been confirmed. Therefore, the potential for omalizumab in other chronic conditions should be considered. [ABSTRACT FROM AUTHOR]